These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 9007221

  • 1. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G, Hartley C, McElroy P, McCrea C, Kerzic P, McNiece I.
    Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
    [Abstract] [Full Text] [Related]

  • 2. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
    Honda K, Takenaka K, Shinagawa K, Ishimaru F, Ikeda K, Niiya K, Harada M.
    Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
    [Abstract] [Full Text] [Related]

  • 3. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K, Akahori H, Shibuya K, Nitta Y, Ida M, Kusaka M, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
    [Abstract] [Full Text] [Related]

  • 4. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
    Coleman D, Fairchild D, Schindler-Horvat J, Munyakazi L, Neumann TA.
    Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
    [Abstract] [Full Text] [Related]

  • 5. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H.
    Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
    [Abstract] [Full Text] [Related]

  • 6. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

  • 7. Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients.
    Molineux G, Hartley C, McElroy P, McCrea C, McNiece IK.
    Blood; 1996 Jul 01; 88(1):366-76. PubMed ID: 8704197
    [Abstract] [Full Text] [Related]

  • 8. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
    Akahori H, Shibuya K, Ozai M, Ida M, Kabaya K, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov 01; 14(6):678-89. PubMed ID: 8948025
    [Abstract] [Full Text] [Related]

  • 9. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM, MacVittie TJ, Roskos L, Stead RB.
    Stem Cells; 2003 Nov 01; 21(1):79-89. PubMed ID: 12529554
    [Abstract] [Full Text] [Related]

  • 10. Continuous intravenous administration of rmGM-CSF enhances immune as well as hematopoietic reconstitution following syngeneic bone marrow transplantation in mice.
    Naparstek E, Ohana M, Greenberger JS, Slavin S.
    Exp Hematol; 1993 Jan 01; 21(1):131-7. PubMed ID: 8417949
    [Abstract] [Full Text] [Related]

  • 11. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.
    Ann Hematol; 2003 Nov 01; 82(11):677-83. PubMed ID: 14530872
    [Abstract] [Full Text] [Related]

  • 12. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
    Harker LA, Marzec UM, Kelly AB, Cheung E, Tomer A, Nichol JL, Hanson SR, Stead RB.
    Blood; 1997 Jan 01; 89(1):155-65. PubMed ID: 8978288
    [Abstract] [Full Text] [Related]

  • 13. Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graft-versus-host disease and survival after murine haematopoietic stem cell transplantation.
    Atkinson K, Vos B, Kang-Er Z, Guiffre A, Seymour R, Gillis S.
    Cytokines Mol Ther; 1995 Mar 01; 1(1):47-55. PubMed ID: 9384663
    [Abstract] [Full Text] [Related]

  • 14. Thrombopoietin: biology and clinical potentials.
    Miyazaki H, Kato T.
    Int J Hematol; 1999 Dec 01; 70(4):216-25. PubMed ID: 10643146
    [Abstract] [Full Text] [Related]

  • 15. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
    Shibuya K, Akahori H, Takahashi K, Tahara E, Kato T, Miyazaki H.
    Blood; 1998 Jan 01; 91(1):37-45. PubMed ID: 9414267
    [Abstract] [Full Text] [Related]

  • 16. Megakaryocyte growth and development factor stimulates enhanced platelet recovery in mice after bone marrow transplantation.
    Molineux G, Hartley CA, McElroy P, McCrea C, McNiece IK.
    Blood; 1996 Aug 15; 88(4):1509-14. PubMed ID: 8695873
    [Abstract] [Full Text] [Related]

  • 17. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.
    Exp Hematol; 2002 Sep 15; 30(9):1044-50. PubMed ID: 12225796
    [Abstract] [Full Text] [Related]

  • 18. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.
    Farese AM, Hunt P, Grab LB, MacVittie TJ.
    J Clin Invest; 1996 May 01; 97(9):2145-51. PubMed ID: 8621805
    [Abstract] [Full Text] [Related]

  • 19. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
    Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.
    Blood; 1996 Jul 15; 88(2):511-21. PubMed ID: 8695799
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
    Neelis KJ, Dubbelman YD, Qingliang L, Thomas GR, Eaton DL, Wagemaker G.
    Exp Hematol; 1997 Sep 15; 25(10):1084-93. PubMed ID: 9293906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.